Bracco Reaches Major Milestone with 6 Million VUEWAY® Injections Administered Globally

Bracco's Global Achievement: 6 Million VUEWAY® Injections Administered



In a remarkable development for the medical imaging field, Bracco, a leader in diagnostic imaging, proudly announces that it has administered over 6 million doses of its VUEWAY® (gadopiclenol) injection worldwide. This achievement underlines Bracco's ongoing commitment to innovation and excellence in its magnetic resonance imaging (MRI) portfolio, which continues to evolve to meet the demands of healthcare professionals and patients alike.

The VUEWAY injection represents a significant advancement in the realm of gadolinium-based contrast agents (GBCA). Notably, it is a macrocyclic compound with enhanced stability, allowing for effective contrast enhancement at a notably low gadolinium dose of just 0.05 mmol/kg. This aspect of VUEWAY not only aids in providing high-quality imaging but also addresses critical safety considerations, especially for patients needing multiple imaging sessions over time.

Cosimo De Pinto, Executive Vice President of Marketing and Commercial Operations at Bracco Americas, emphasized the importance of this milestone: "Administering 6 million doses of VUEWAY globally reflects its growing significance in aiding radiologists to make informed decisions for their patients. The unique molecular design of VUEWAY contributes to the highest relaxivity per gadolinium ion among FDA-approved GBCAs in the US, enabling us to offer a low-dose option to a diverse patient population, including the very young."

Since its initial regulatory approval in 2022, VUEWAY has expanded its reach into international markets, significantly enhancing access to pediatric patients by including neonates and infants in its approved indications as of 2026. This expansion plays a vital role in ensuring that the youngest and most vulnerable patients can benefit from low-dose contrast-enhanced MRI, an essential tool for accurately diagnosing various conditions.

Bracco's strategy extends beyond just delivering a contrast agent. The company is committed to broader research and innovation in MRI technology. Its portfolio includes the Max 3™ Injector and AiMIFY® Software, both designed to refine the imaging process and enhance patient care.

Innovations in MRI Technology


The Max 3™ Rapid-Exchange, Syringeless MR Injector is a state-of-the-art tool designed to streamline workflows and contrast delivery. Its innovative cable-free, closed-system design minimizes waste while ensuring efficient contrast use. The device includes features such as automatic air detection and particle filtration, significantly enhancing patient safety during imaging procedures.

Additionally, Bracco's AiMIFY® Software integrates artificial intelligence to improve the evaluation of MRI images. Developed in collaboration with Subtle Medical, AiMIFY enhances contrast in post-contrast brain MRI images, allowing for better visualization of lesions and providing radiologists with vital imaging data that can lead to improved patient outcomes. Recognized as the Best New Radiology Software at the AuntMinnie.com's 2026 Minnies Awards, AiMIFY exemplifies Bracco's commitment to leveraging technology to improve diagnostic accuracy.

Commitment to the Future


The administration of 6 million doses not only signifies Bracco’s present success but also sets a robust foundation for future innovations. With nearly a century of expertise in diagnostic imaging, Bracco remains dedicated to expanding its MRI portfolio in collaboration with the radiology community. This partnership ensures that clinicians can deliver effective and precise care to patients today and in the years to come.

As Bracco continues to enhance its offerings, industry stakeholders and radiology professionals eagerly anticipate what the future holds in diagnostic imaging—a future where enhanced patient care and informed clinical decisions are paramount.

For more information about VUEWAY and its associated technologies, as well as important safety information regarding its use, visit Bracco’s official website or contact their medical representatives directly.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.